Form 8-K - Current report:
SEC Accession No. 0000950170-25-065786
Filing Date
2025-05-07
Accepted
2025-05-07 16:35:10
Documents
13
Period of Report
2025-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krro-20250507.htm   iXBRL 8-K 57904
2 EX-99.1 krro-ex99_1.htm EX-99.1 148291
3 GRAPHIC img174420225_0.jpg GRAPHIC 11939
  Complete submission text file 0000950170-25-065786.txt   364780

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT krro-20250507.xsd EX-101.SCH 32947
16 EXTRACTED XBRL INSTANCE DOCUMENT krro-20250507_htm.xml XML 4884
Mailing Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141
Business Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 25922026
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)